1.Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, Xu X, Cheung T, Burley JR, Sun H et al.. (2021) Development of CVN424: a selective and novel GPR6 inverse agonist effective in models of Parkinson's Disease.. J Pharmacol Exp Ther, 129 (3):(589-97). [PMID:33795395]
2.Sun H, Monenschein H, Schiffer HH, Reichard HA, Kikuchi S, Hopkins M, Macklin TK, Hitchcock S, Adams M, Green J et al.. (2021) First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.. J Med Chem, 129 (3):(589-97). [PMID:33861086]
3.Margolin DH, Brice NL, Davidson AM, Matthews KL, Carlton MBL. (2022) A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.. J Pharmacol Exp Ther, 381 (1):(33-41). [PMID:35110393]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
